EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeks Results reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by ta

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeks Results reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13, two key drivers of type 2 inflammation TARRYTOWN, N.Y. and PARIS, June 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today presented posit

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patientsLonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NA

Nylabone, an iconic brand in the Central Garden & Pet portfolio (NASDAQ:CENT) (NASDAQ:CENTA), is bringing even more tail-wagging joy to treat time with the launch of Nubz® Flavor Bursts chew treats – a flavorful addition to its popular Nubz® dog treat line, just in time for summer snacking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615973236/en/Crafted with a highly digestible potato starch recipe, Nubz® Flavor Bursts contain no artificial preservatives, colors, or fillers. They also feature the brand's namesake dental textures to promote healthy teeth and gums, can easily break in half for smaller treats, and are proudl

Goldman upgraded Suzano S.A. from Neutral to Buy

Goldman reiterated coverage of Monster Beverage with a rating of Buy and set a new price target of $72.00 from $67.00 previously

Wells Fargo reiterated coverage of Monster Beverage with a rating of Overweight and set a new price target of $70.00 from $67.00 previously

Argus initiated coverage of Deckers Outdoor with a rating of Hold

4 - Chime Financial, Inc. (0001795586) (Issuer)

4 - Trinity Capital Inc. (0001786108) (Issuer)

4 - ON24 INC. (0001110611) (Issuer)

4 - Grove Collaborative Holdings, Inc. (0001841761) (Issuer)

4 - Navitas Semiconductor Corp (0001821769) (Issuer)

4 - Navitas Semiconductor Corp (0001821769) (Issuer)

4 - Chime Financial, Inc. (0001795586) (Issuer)

4 - Chime Financial, Inc. (0001795586) (Issuer)

SCHEDULE 13D/A - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Subject)

SCHEDULE 13D/A - Solidion Technology Inc. (0001881551) (Subject)

144 - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

144 - Coupang, Inc. (0001834584) (Subject)

For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

MINNEAPOLIS, June 13, 2025 /PRNewswire/ -- Target Corporation (NYSE: TGT) today announced voting results from its 2025 Annual Meeting of Shareholders held on June 11, 2025 ("Annual Meeting"). Shareholders elected all 12 nominees for the board of directors, ratified the appointment of Target's independent registered public accounting firm, approved the advisory "Say on Pay" management proposal, and rejected one shareholder proposal. The Carideo Group, the independent Inspector of Election, has certified all voting results for the Annual Meeting. The final tabulation indicates that 391,209,355 shares were voted, representing approximately 86.1 percent of Target's outstanding shares as of the r

FuboTV Inc. (d/b/a Fubo) (NYSE:FUBO), the leading sports-first live TV streaming platform, today announced that on June 11, 2025, the Compensation Committee of Fubo's Board of Directors granted restricted stock unit awards covering an aggregate of 33,497 shares of its common stock to nine new employees to induce them to join Fubo. The awards were granted under Fubo's 2024 Employment Inducement Equity Incentive Plan, and vest annually over a four-year period following their grant, subject to continued employment. The awards were granted as employment inducement awards pursuant to the New York Stock Exchange rules. About Fubo With a global mission to aggregate the best in TV, including pr

WESTERLY, R.I., June 13, 2025 /PRNewswire/ -- Washington Trust ("the Bank") is proud to announce its recognition as one of the 2025 Best Places to Work in Rhode Island by Providence Business News (PBN) for the 15th consecutive year. The 2025 honorees were celebrated at a special ceremony on Thursday, June 12, at the Crowne Plaza in Warwick, RI. "We are incredibly proud to be recognized on Rhode Island's Best Places to Work list for the fifteenth consecutive year," said Edward O. "Ned" Handy III, Chairman & CEO of Washington Trust. "This achievement reflects our steadfast commi

VALLETTA, Malta, June 13, 2025 (GLOBE NEWSWIRE) -- As Meridianbet prepares to join the global celebration of World Blood Donor Day on June 14, the company is once again turning corporate values into direct action. Across multiple countries and markets, Meridianbet and the Meridianbet Foundation are organizing and participating in voluntary blood donation drives, reaffirming a long-standing commitment to public health and community solidarity. Meridianbet Joins Global Effort to Tackle Blood Shortages, Turning Employee Action into Lifesaving Impact In 2025, the blood donation remains a very important, and unresolved issue. Globally, around 118.5 million units of blood a

Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit

- The Company is developing an enhanced immunosuppressive regimen in consultation with a panel of multi-disciplinary clinical experts and engaging with regulators - Shipments of ELEVIDYS for infusions in non-ambulatory patients in commercial setting are suspended until enhanced regimen is approved and in place - ENVISION study is paused while seeking a protocol amendment to incorporate additional immunosuppression - Sarepta to host investor call on June 16, 2025, at 8:00 am Eastern time Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only a

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell drive

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Ready Capital Corporation (NYSE:RC) (the "Company") announced that its Board of Directors declared a quarterly cash dividend of $0.125 per share of common stock and Operating Partnership unit for the quarter ended June 30, 2025. This dividend is payable on July 31, 2025, to shareholders of record as of the close of business on June 30, 2025. Additionally, the Company announced that its Board of Directors declared quarterly cash dividends on its 6.25% Series C Cumulative Convertible Preferred Stock (the "Series C Preferred Stock"), and its 6.50% Series E Cumulative Redeemable Preferred Stock (the "Series E Preferred Stock"). The Company decl

SC 13D/A - ALLIANCEBERNSTEIN HOLDING L.P. (0000825313) (Subject)

SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

SC 13D/A - INCOME OPPORTUNITY REALTY INVESTORS INC /TX/ (0000949961) (Subject)

SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

Recently, on July 4, 2024, a significant insider purchase was recorded at Allied Gaming & Entertainment Inc. as Large owner Choi Roy bought $456,750 worth of shares (360,000 units at $1.27), increasing direct ownership by 14% to 2,871,822 units (SEC Form 4). This purchase is notable for the size of the transaction and the percentage increase in direct ownership, indicating a strong belief in the company's future prospects. Insider purchases are generally viewed positively by investors as they signal confidence from those with intimate knowledge of the company's operations. Examining other recent insider transactions at Allied Gaming & Entertainment Inc., we notice a few patterns worth explo

Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan